Main > ONCOLOGY (**) > BTC>Advanced or MET>Treat.> > TREAT.: > US. M. PD-L1 MAb+CT (gemcitabine+ci

---

splatin

US. M. PD-L1 MAb+CT (gemcitabine+ci's subsections
(*) EU CE Mark Date: 2023. 12.18
(*) USA Approval Date: 2023. 11.01
Company
PD-L1 MAb Generic Name
RTM
RTM Web-Site
USA Patent Numbers

US. M. PD-L1 MAb+CT (gemcitabine+ci's products
This section has no products